# DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease

> **NCT05685394** · PHASE4 · UNKNOWN · sponsor: **University of Campinas, Brazil** · enrollment: 80 (estimated)

## Conditions studied

- End-stage Kidney Disease

## Interventions

- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT05685394
- **Lead sponsor:** University of Campinas, Brazil
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-24
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05685394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05685394, "DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05685394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*